Technical Analysis for EGRX - Eagle Pharmaceuticals, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Up | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
20 DMA Resistance | Bearish | 0.00% | |
Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
Outside Day | Range Expansion | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Pocket Pivot | Bullish Swing Setup | -7.11% | |
Outside Day | Range Expansion | -7.11% | |
20 DMA Resistance | Bearish | -6.49% | |
Earnings Movers | Other | -1.92% | |
Fell Below 20 DMA | Bearish | -4.26% |
Alert | Time |
---|---|
Outside Day | about 16 hours ago |
Down 5% | about 16 hours ago |
Fell Below Lower Bollinger Band | about 16 hours ago |
Fell Below Previous Day's Low | about 16 hours ago |
Lower Bollinger Band Support | about 16 hours ago |
Get a Trading Sidekick!
- Earnings date: 03/11/2024
Eagle Pharmaceuticals, Inc. Description
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company markets EP-1101 (argatroban) to treat heparin-induced thrombocytopenia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and non-Hodgkin's lymphoma; Ryanodex, a dantrolene to treat malignant hyperthermia; and EP-4104, a dantrolene that has completed a Phase I clinical study for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, which is in pre-clinical formulation and toxicology studies to treat lung cancer; EP-6101, a bivalirudin RTU liquid formulation for the treatment of percutaneous transluminal angioplasty; and EP-2101 (topotecan) to treat ovarian, cervical, and small-cell lung cancers. Eagle Pharmaceuticals, Inc. was founded in 2007 and is based in Woodcliff Lake, New Jersey.
Classification
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Pharmaceutical Lymphoma Small Cell Lung Cancer Stroke Lung Cancer Toxicology Chronic Lymphocytic Leukemia Lymphocytic Leukemia Organic Chemistry Angioplasty Percutaneous Thrombocytopenia Heparin Treatment Of Chronic Lymphocytic Leukemia Nitrogen Mustards
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 32.4 |
52 Week Low | 4.1 |
Average Volume | 247,929 |
200-Day Moving Average | 12.28 |
50-Day Moving Average | 5.54 |
20-Day Moving Average | 6.14 |
10-Day Moving Average | 6.06 |
Average True Range | 0.45 |
RSI (14) | 44.44 |
ADX | 14.26 |
+DI | 16.76 |
-DI | 21.21 |
Chandelier Exit (Long, 3 ATRs) | 5.45 |
Chandelier Exit (Short, 3 ATRs) | 6.57 |
Upper Bollinger Bands | 6.65 |
Lower Bollinger Band | 5.62 |
Percent B (%b) | 0.0 |
BandWidth | 16.82 |
MACD Line | 0.05 |
MACD Signal Line | 0.13 |
MACD Histogram | -0.0825 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 6.60 | ||||
Resistance 3 (R3) | 6.68 | 6.43 | 6.43 | ||
Resistance 2 (R2) | 6.43 | 6.19 | 6.39 | 6.38 | |
Resistance 1 (R1) | 6.03 | 6.03 | 5.91 | 5.95 | 6.32 |
Pivot Point | 5.78 | 5.78 | 5.72 | 5.74 | 5.78 |
Support 1 (S1) | 5.38 | 5.54 | 5.26 | 5.30 | 4.92 |
Support 2 (S2) | 5.13 | 5.38 | 5.09 | 4.86 | |
Support 3 (S3) | 4.73 | 5.13 | 4.81 | ||
Support 4 (S4) | 4.65 |